Abstract
Background Myelo-ablative therapy with peripheral blood progenitor cell (PBPC) support is increasingly being used in patients with haematological malignancy considered to be at high risk for recurrence. The results of this approach, in comparison with the previous experience at St. Bartholomew's Hospital (SBH) using autologous bone marrow transplantation form the basis of this report. Patients and methods 42 patients (age range 18–63 years, median 42 years), deemed to have a poor prognosis with conventional therapy received myelo-ablative therapy with PBPC support. Diagnoses comprised: non-Hodgkin's lymphoma (NHL): 16 patients, Hodgkin's disease (HD): 9, Multiple Myeloma (MM): 12, and solid tumours (ST): 5. PBPC were mobilised using adriamycin: 35 mg/m2 i.v. on day 1 and etoposide 100 mg/m2 orally, days 1–5, followed by G-CSF: 5 ng/kg, subcutaneously, for a median of 7 days (range 6–9 days). Results A total of 67 PBPC collections were performed, 1 being ‘sufficient’ (i.e. mononuclear cells > 1.5×108/g and CD34+ cells >1×106/kg) in 21 of the 42 patients. The median time to haematological recovery following reinfusion of PBPC was 13 days for both neutrophils >0.5×109/I and platelets >20×109/I (ranges: 8–27, and 8–48 days, respectively) which is significantly shorter than for patients in the historical control group. Supportive care requirements were also significantly reduced, as was the duration of hospital stay i.e., median 19 days (range 12–73 days) compared with 29 days (range 9–180 days). Conclusion These results confirm rapid blood count recovery following myelo-ablative therapy with PBPC support and the feasibility of this approach.